Stocks · News reference

Fractyl Health Helps Maintain Weight After Stopping Popular Obesity Drugs, Stock Soars

Jul 15, 2026, 6:22 PMVandana Singh

Fractyl Health reported one-year REMAIN-1 data showing Revita reduced weight regain after GLP-1 therapy with favorable safety results.

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

BenzingaAug 10, 2026, 8:07 PMBenzinga Newsdesk
Fractyl Health Q2 EPS $(0.16) Misses $(0.13) Estimate
Fractyl Health (NASDAQ:GUTS) reported quarterly losses of $(0.16) per share which missed the analyst consensus estimate of $(0.13) by 23.08 percent. This is a 71.93 percent increase over losses of $(0.57) per share from
GUTS
BenzingaJul 15, 2026, 6:21 PMBenzinga Newsdesk
Fractyl Health shares are trading higher after the company announced randomized data from REMAIN-1 Midpoint Cohort demonstrating durable weight maintenance one year after GLP-1 discontinuation.
GUTS
BenzingaJul 15, 2026, 10:02 AMBenzinga Newsdesk
Fractyl Health Announces One-Year Results From Its REMAIN-1 Midpoint Cohort; Results Reinforce Potential Of Revita DMR System To Become First Durable Therapy For Post-GLP-1 Weight Maintenance
Key Findings:Dose-dependent durability confirmed at one year: In the full modified intention-to-treat (mITT) population (N=45), a single Revita procedure reduced weight regain by approximately 40% versus sham at one
GUTS